What is the benefit of achieving 50% LDL-C lowering in adults with diabetes mellitus who have 20% ASCVD risk?
A CTT analysis has shown that the higher the 10-year ASCVD risk, the greater is the benefit from increased LDL-C reduction. This is supported by meta-analyses comparing high-intensity versus low-intensity statin therapy and those comparing the benefit of statins and nonstatin therapeutic agents such as ezetimibe, bile sequestrants, and PCSK9 antagonists. Thus, achieving 50% LDL-C lowering in adults with diabetes mellitus who have 20% ASCVD risk can be beneficial in reducing their risk of ASCVD.